Key result
GWAS identify genetic loci linked to CAD risk, advancing novel treatments in lipid metabolism.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Genome-wide association studies have identified numerous loci associated with coronary artery disease, paving the way for novel lipid metabolism treatments and polygenic risk scores for personalized medicine.
Many cardiovascular diseases are facilitated by strong inheritance. For example, large-scale genetic studies identified hundreds of genomic loci that affect the risk of coronary artery disease. At each of these loci, common variants are associated with disease risk with robust statistical evidence but individually small effect sizes. Only a minority of candidate genes found at these loci are involved in the pathophysiology of traditional risk factors, but experimental research is making progress in identifying novel, and, in part, unexpected mechanisms. Targets identified by genome-wide association studies have already led to the development of novel treatments, specifically in lipid metabolism. This review summarizes recent genetic and experimental findings in this field. In addition, the development and possible clinical usefulness of polygenic risk scores in risk prediction and individualization of treatment, particularly in lipid metabolism, are discussed.
No takes yet. Share an insight, caveat, or question.
Kessler et al. (2021) studied this question. Genome-wide association studies have identified numerous genetic loci associated with coronary artery disease risk, advancing novel treatments in lipid metabolism.
Synapse has enriched 10 related papers. Consider them for comparative context: